Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to -$2.8 million.

  • Fortress Biotech's Change in Accured Expenses rose 4332.67% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.9 million, marking a year-over-year increase of 3149.43%. This contributed to the annual value of -$6.4 million for FY2024, which is 7379.21% up from last year.
  • Per Fortress Biotech's latest filing, its Change in Accured Expenses stood at -$2.8 million for Q3 2025, which was up 4332.67% from -$8.4 million recorded in Q2 2025.
  • Fortress Biotech's Change in Accured Expenses' 5-year high stood at $28.1 million during Q3 2021, with a 5-year trough of -$17.5 million in Q3 2023.
  • Its 5-year average for Change in Accured Expenses is $538684.2, with a median of $590000.0 in 2025.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 225108.7% in 2021, then plummeted by 829295.77% in 2023.
  • Over the past 5 years, Fortress Biotech's Change in Accured Expenses (Quarter) stood at $9.4 million in 2021, then plummeted by 57.89% to $3.9 million in 2022, then plummeted by 286.95% to -$7.4 million in 2023, then soared by 109.89% to $728000.0 in 2024, then crashed by 488.46% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, -$8.4 million for Q2 2025, and $590000.0 during Q1 2025.